Other Species / Isoforms
  SOCS3 (mouse)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K6
__MVTHSKFPAAGMS
1 0
SOCS3 (human) __MVTHSkFPAAGMS K6-ub
SOCS3 (mouse) __MVTHSKFPAAGMS K6
SOCS3 (rat) __MVTHSKFPAAGMS K6
K23
LDTSLRLKTFSSKSE
0 1
SOCS3 (human) LDTSLRLkTFSSKSE K23-ub
SOCS3 (mouse) LDTSLRLKTFSSKSE K23
SOCS3 (rat) LDTSLRLKTFSSKSE K23
T86
FFTLSVKTQSGTKNL
0 1
SOCS3 (human) FFTLSVKtQSGTKNL T86-p
SOCS3 (mouse) FFTLSVKTQSGTKNL T86
SOCS3 (rat) FFTLSVETQSGTKNL T86
Y165
GSTPKRAYYIYSGGE
0 1
SOCS3 (human) GSPPRRAyyIYSGGE Y165-p
SOCS3 (mouse) GSTPKRAYYIYSGGE Y165
SOCS3 (rat) GGTPKRAYYIYSGGE Y165
Y166
STPKRAYYIYSGGEK
0 1
SOCS3 (human) SPPRRAyyIYSGGEK Y166-p
SOCS3 (mouse) STPKRAYYIYSGGEK Y166
SOCS3 (rat) GTPKRAYYIYSGGEK Y166
K195
TLQHLCRKTVNGHLD
0 1
SOCS3 (human) TLQHLCRkTVNGHLD K195-ub
SOCS3 (mouse) TLQHLCRKTVNGHLD K195
SOCS3 (rat) TLQHLCRKTVNGHLD K195
Y204-p
VNGHLDSyEKVTQLP
Upstream
Downstream
5 13
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • INSR (human)
Putative in vivo kinases:
  • JAK2 (human)
Treatment
  • GH
  • insulin
  • LIF
  • ruxolitinib
SOCS3 (human) VNGHLDSyEkVTQLP Y204-p
SOCS3 (mouse) VNGHLDSyEKVTQLP Y204-p
SOCS3 (rat) VNGHLDSYEKVTQLP Y204
K206
GHLDSyEKVTQLPGP
0 1
SOCS3 (human) GHLDSyEkVTQLPGP K206-ub
SOCS3 (mouse) GHLDSyEKVTQLPGP K206
SOCS3 (rat) GHLDSYEKVTQLPGP K206
Y221-p
IREFLDQyDAPL___
Upstream
Downstream
4 0
Effects on Biological Processes:
  • carcinogenesis, inhibited
  • cell cycle regulation
  • cell growth, inhibited
Treatment
  • ruxolitinib
SOCS3 (human) IREFLDQyDAPL___ Y221-p
SOCS3 (mouse) IREFLDQyDAPL___ Y221-p
SOCS3 (rat) IREFLDQYDAPL___ Y221